ALX Oncology (NASDAQ:ALXO), Inc. is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.
The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors. Evorpacept is being evaluated in multiple Phase 2 clinical trials, both as monotherapy and in combination regimens, across cancers such as head and neck, gastric, and non-small cell lung cancer.
In addition to evorpacept, ALX Oncology is advancing NX-1607, an oral small-molecule inhibitor of CBL-B, a key intracellular checkpoint that regulates T-cell and natural killer cell activation. By targeting CBL-B, NX-1607 aims to lower the activation threshold of effector immune cells, potentially broadening the scope of patients who may respond to immunotherapy. NX-1607 is currently in Phase 1 studies, being tested alone and in combination with checkpoint inhibitors.
ALX Oncology conducts its clinical studies in the United States and collaborates internationally to enroll patients across multiple sites. The company was founded to address unmet needs in cancer treatment by strategically combining innate and adaptive immune modulators. Its leadership team brings experience in drug development, clinical operations, and regulatory affairs from prior roles at leading biopharmaceutical companies.
